Adomeglivant

Adomeglivant (LY2409021) is a potent, selective glucagon receptor (GluR) allosteric antagonist. Adomeglivant is widely used in the research for type 2 diabetes mellitus[1][2][3].

Product Specifications

CAS Number

[1488363-78-5]

Product Name Alternative

LY2409021

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

GCGR

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Adomeglivant.html

Purity

99.63

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(O)CCNC(C1=CC=C([C@@H](OC2=CC(C)=C(C3=CC=C(C(C)(C)C)C=C3)C(C)=C2)CCC(F)(F)F)C=C1)=O

Molecular Formula

C32H36F3NO4

Molecular Weight

555.63

Precautions

H302, H315, H319, H335

References & Citations

[1]Sonam Grover, et al. Computational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus. BMC Bioinformatics. 2014; 15 (Suppl 16) : S13.|[2]Oleg G Chepurny, et al. Non-conventional glucagon and GLP-1 receptor agonist and antagonist interplay at the GLP-1 receptor revealed in high-throughput FRET assays for cAMP. J Biol Chem. 2019 Mar 8;294 (10) :3514-3531.|[3]Angela Kim, et al. AVP-induced counter-regulatory glucagon is diminished in type 1 diabetes. bioRxiv. January 31, 2020.